Nanomedicine in Psychiatry

New Therapeutic Opportunities from Research on Small RNAs

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Preclinical Research Alterations in small non-coding RNAs have been observed in many human disease states including cancer, cardiovascular, developmental, neurological, and psychiatric disorders. These molecules have recently raised the interest of the scientific community for novel therapeutic approaches. Nanotechnologies, including the development of sophisticated nanoparticles, offer new ways for the delivery of small RNA-based therapies. The nanoparticle delivery method appears attractive, but so far most of the work in this area has been conducted in the context of cancer. New therapeutic strategies are needed for psychiatric disorders, where treatment is often ineffective, leading to frequent patient hospitalizations and a growing economic burden. In this article, we discuss the role of small RNAs in psychiatric diseases and how this new knowledge, combined with innovations in nanotechnologies, could lead to the development of novel therapeutic approaches.

Original languageEnglish
Pages (from-to)453-457
JournalDrug Development Research
Volume77
Issue number8
DOIs
Publication statusPublished - 2016

Fingerprint

Nanomedicine
Therapeutic Human Experimentation
Psychiatry
RNA
Nanotechnology
Nanoparticles
Therapeutic Community
Small Untranslated RNA
Therapeutics
Nervous System Diseases
Neoplasms
Hospitalization
Economics
Research

Keywords

  • MicroRNAs
  • Nanomedicine
  • Psychiatry
  • Small RNAs

ASJC Scopus subject areas

  • Drug Discovery

Cite this

Nanomedicine in Psychiatry : New Therapeutic Opportunities from Research on Small RNAs. / Milanesi, Elena; Maj, Carlo; Bocchio-Chiavetto, Luisella; Maffioletti, Elisabetta.

In: Drug Development Research, Vol. 77, No. 8, 2016, p. 453-457.

Research output: Contribution to journalArticle

@article{ff4de91c5dfe40b2842cd3958c7d9b70,
title = "Nanomedicine in Psychiatry: New Therapeutic Opportunities from Research on Small RNAs",
abstract = "Preclinical Research Alterations in small non-coding RNAs have been observed in many human disease states including cancer, cardiovascular, developmental, neurological, and psychiatric disorders. These molecules have recently raised the interest of the scientific community for novel therapeutic approaches. Nanotechnologies, including the development of sophisticated nanoparticles, offer new ways for the delivery of small RNA-based therapies. The nanoparticle delivery method appears attractive, but so far most of the work in this area has been conducted in the context of cancer. New therapeutic strategies are needed for psychiatric disorders, where treatment is often ineffective, leading to frequent patient hospitalizations and a growing economic burden. In this article, we discuss the role of small RNAs in psychiatric diseases and how this new knowledge, combined with innovations in nanotechnologies, could lead to the development of novel therapeutic approaches.",
keywords = "MicroRNAs, Nanomedicine, Psychiatry, Small RNAs",
author = "Elena Milanesi and Carlo Maj and Luisella Bocchio-Chiavetto and Elisabetta Maffioletti",
year = "2016",
doi = "10.1002/ddr.21344",
language = "English",
volume = "77",
pages = "453--457",
journal = "Drug Development Research",
issn = "0272-4391",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Nanomedicine in Psychiatry

T2 - New Therapeutic Opportunities from Research on Small RNAs

AU - Milanesi, Elena

AU - Maj, Carlo

AU - Bocchio-Chiavetto, Luisella

AU - Maffioletti, Elisabetta

PY - 2016

Y1 - 2016

N2 - Preclinical Research Alterations in small non-coding RNAs have been observed in many human disease states including cancer, cardiovascular, developmental, neurological, and psychiatric disorders. These molecules have recently raised the interest of the scientific community for novel therapeutic approaches. Nanotechnologies, including the development of sophisticated nanoparticles, offer new ways for the delivery of small RNA-based therapies. The nanoparticle delivery method appears attractive, but so far most of the work in this area has been conducted in the context of cancer. New therapeutic strategies are needed for psychiatric disorders, where treatment is often ineffective, leading to frequent patient hospitalizations and a growing economic burden. In this article, we discuss the role of small RNAs in psychiatric diseases and how this new knowledge, combined with innovations in nanotechnologies, could lead to the development of novel therapeutic approaches.

AB - Preclinical Research Alterations in small non-coding RNAs have been observed in many human disease states including cancer, cardiovascular, developmental, neurological, and psychiatric disorders. These molecules have recently raised the interest of the scientific community for novel therapeutic approaches. Nanotechnologies, including the development of sophisticated nanoparticles, offer new ways for the delivery of small RNA-based therapies. The nanoparticle delivery method appears attractive, but so far most of the work in this area has been conducted in the context of cancer. New therapeutic strategies are needed for psychiatric disorders, where treatment is often ineffective, leading to frequent patient hospitalizations and a growing economic burden. In this article, we discuss the role of small RNAs in psychiatric diseases and how this new knowledge, combined with innovations in nanotechnologies, could lead to the development of novel therapeutic approaches.

KW - MicroRNAs

KW - Nanomedicine

KW - Psychiatry

KW - Small RNAs

UR - http://www.scopus.com/inward/record.url?scp=84993927158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84993927158&partnerID=8YFLogxK

U2 - 10.1002/ddr.21344

DO - 10.1002/ddr.21344

M3 - Article

VL - 77

SP - 453

EP - 457

JO - Drug Development Research

JF - Drug Development Research

SN - 0272-4391

IS - 8

ER -